Qatar Cardiometabolic Cohort

NCT07675928 | Not Yet Recruiting

• 1 other identifier: 26-00001
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.

Conditions

Cardiometabolic Diseases

Keywords

cardiometabolic diseases; atherosclerotic cardiovascular disease; diabetes

Outcome Measures

Primary Outcomes (1)

• Comparison of the incidence of the of major adverse cardiovascular events between the three groups (control, pre-diabetes, and diabetes)

  To compare the incidence of major adverse cardiovascular events (3-point MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) across three groups of adults with established ASCVD or very high cardiovascular risk: non-diabetes, pre-diabetes, and type 2 diabetes.

  Baseline, Year 1, and Year 5

Secondary Outcomes (21)

• Change in body mass index (BMI)

  Baseline, Year 1, and Year 5

• Change in waist-to-hip ratio

  Baseline, Year 1, and Year 5

• Change in fasting glucose

  Baseline, Year 1, and Year 5.

• Change in glycated hemoglobin (HbA1c)

  Baseline, Year 1, and Year 5

• Change in lipid profile parameters

  Baseline, Year 1, and Year 5.

Study Arms (3)

Groupe 1: Controls (C)

Non-diabetic patients, defined as having an HbA1c \< 5.7%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk

Groupe 2: Cases-1 (pre-D)

Patients with pre-diabetes, defined as having an HbA1c between 5.7≤HbA1C ≤6.4, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk

Groupe 3: Cases-2 (T2D)

Patients with type 2 diabetes, defined as having an HbA1c ≥ 6.5%, with established atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be recruited at Hamad Medical Corporation

You may qualify if:

• Qataris
• Long-term residents (≥15 years of residence in Doha) who are not planning to leave Qatar voluntarily within the next 5 years.
• Age ≥18 years.
• English or Arabic speaker.
• Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.
• ASCVD:
• ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes.
• i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories:
• Coronary Artery Disease (CAD)
• Myocardial infarction (ST-elevation myocardial infarction (STEMI) or Non-ST-elevation myocardial infarction (NSTEMI))
• Stable or unstable angina with angiographic stenosis ≥50%
• History of coronary revascularization (Percutaneous coronary intervention (PCI) or Coronary artery bypass graft surgery (CABG))
• Cerebrovascular Disease
• Ischemic stroke or transient ischemic attack (TIA)
• Symptomatic carotid artery stenosis ≥50% or prior carotid intervention

You may not qualify if:

• Type 1 diabetes or monogenic diabetes (e.g., MODY).
• Pregnancy (self-reported).
• Active cancer, under medical or radiation therapy or terminal, or cancer in remission \< 1 year.
• Chronic immune or chronic infectious diseases.
• End stage renal disease (ESRD) (estimated glomerular filtration rate \<15 mL/min/1.73m²).
• Prisoners.
• Inability or unwillingness to provide informed consent, including language barriers.
• Mental incapacity.

Sponsors & Collaborators

• Weill Cornell Medical College in Qatar: lead
• Hamad Medical Corporation: collaborator

Study Sites (1)

Hamad Medical Corporation

Doha, Qatar

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood and Urine

MeSH Terms

Conditions

Atherosclerosis; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Charbel Abi Khalil, MD,PhD

  Weill Cornell Medicine-Qatar

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Charbel Abi khalil, MD,PhD

CONTACT

+974 4492 8484; cha2022@qatar-med.cornell.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2026
• First Posted: June 30, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 30, 2036
• Study Completion (Estimated): June 30, 2036
• Last Updated: June 30, 2026

Record last verified: 2026-04

Locations

QA (1)